AOD-9604 — Growth Hormone C-terminal Lipolytic Fragment

Discovery and Background

AOD-9604 emerged from a targeted programme at Monash University, Melbourne, in the nineteen-nineties. Researchers led by Mark Heffernan and colleagues set out to isolate the functional domains of human growth hormone (hGH) responsible for its well-documented lipolytic activity — the capacity to mobilise stored fat — while separating those effects from the hormone's growth-promoting and insulin-desensitising properties.

Human growth hormone is a large, pleiotropic molecule with a molecular weight exceeding twenty-two kilodaltons. Classical work had shown that the C-terminal region spanning roughly residues 177 through 191 of mature hGH contained the lipolytic pharmacophore. Heffernan's team synthesised a truncated analogue of this region, adding a disulphide bridge to confer structural stability and improve plasma half-life. The resulting compound was designated AOD-9604 — shorthand for "Anti-Obesity Drug 9604" — and given the formal sequence designation hGH(176-191) in the modified numbering conventions used by different research groups.

Early in-vitro and rodent work published in the late nineteen-nineties established that AOD-9604 retained robust lipolytic activity and, critically, did so without engaging the canonical GH receptor. This receptor-selectivity finding distinguished AOD-9604 from native hGH and from peptide secretagogues that amplify whole-axis signalling. It positioned the compound as a mechanistically novel tool for studying adipose biology and, commercially, as a potential pharmaceutical candidate for obesity management. Metabolic Pharmaceuticals Ltd subsequently acquired the intellectual property and advanced AOD-9604 through Phase I and Phase II clinical evaluation in the early two-thousands.

---

Mechanism of Action

AOD-9604 exerts its primary pharmacological effect through the β3-adrenergic receptor (β3-AR) pathway rather than through the somatotropic axis. β3-adrenergic receptors are expressed predominantly in adipose tissue — especially brown adipose tissue — and their activation triggers adenylyl cyclase, raises cyclic AMP, and ultimately phosphorylates hormone-sensitive lipase, releasing stored fatty acids from triglyceride stores.

The mechanism can be summarised in three steps. First, AOD-9604 engages lipid-regulatory signalling without binding the GH receptor dimer or inducing JAK2/STAT5 phosphorylation characteristic of native hGH. Second, downstream cyclic-AMP accumulation activates protein kinase A and hormone-sensitive lipase in a manner qualitatively similar to catecholamine-driven lipolysis. Third, fatty acids released into the circulation are available for oxidative metabolism, which in rodent models translated into measurable reductions in adipose depot mass [PMID:11673762].

Because GH-receptor activation is absent, IGF-1 secretion from the liver remains unchanged. This is a pharmacologically important distinction: exogenous hGH raises IGF-1, which promotes tissue growth, induces insulin resistance, and — at supraphysiological doses — carries risks including acromegalic changes and increased oncogenic signalling. AOD-9604 bypasses these concerns entirely. Ng et al. confirmed in human adipocyte cell lines that AOD-9604 stimulated lipolysis in a dose-dependent fashion without any measurable IGF-1 induction [PMID:11146367]. Insulin sensitivity markers also remained unperturbed in these studies, reinforcing the receptor-selective profile.

---

Researched Applications

Adipose Mass Reduction

The most extensively studied application is reduction of excess adipose tissue. In the landmark Heffernan obese-mouse study, animals receiving AOD-9604 showed significantly greater reductions in body-fat mass compared with vehicle controls, and the effect was accompanied by reduced food-driven lipogenesis as well as increased lipolysis [PMID:11673762]. Lean mass was preserved, consistent with the absence of GH-receptor activation and the correspondingly low anabolic drive.

Human Phase II and Phase IIb trials conducted by Metabolic Pharmaceuticals in the early two-thousands enrolled overweight and obese adults. Participants received AOD-9604 by subcutaneous injection over twelve to twenty-four weeks. Results showed modest but statistically significant reductions in adipose mass relative to placebo, with the strongest effects observed in abdominal adipose depots. The compound was not advanced to Phase III; commercial reasons rather than safety signals appear to have been the primary factor in the programme's discontinuation.

Joint and Cartilage Research

A secondary and more recent line of investigation concerns AOD-9604's potential chondroprotective properties. Goldstein and colleagues reported early-stage findings suggesting the peptide may support cartilage matrix integrity and dampen catabolic cytokine activity in articular tissue. The mechanism proposed involves modulation of the same adipokine-signalling environment that governs fat-cell function, given that adipose tissue and cartilage share overlapping inflammatory regulatory pathways. This area remains exploratory and well short of clinical validation, but it has sustained research interest in the compound beyond its original obesity indication.

---

Dosing Protocols (Research Context)

Subcutaneous administration is the most bioavailable and most commonly used route in human research. A dose of three hundred micrograms per day, administered to the abdomen in a fasted state — typically first thing in the morning — was used across multiple clinical studies. The fasted state is considered important because elevated insulin suppresses lipolysis; administering AOD-9604 against a low-insulin background allows downstream lipase activation to proceed without hormonal antagonism.

Some protocols extend the daily dose to five hundred micrograms where tolerability allows, though evidence supporting superior outcomes at higher doses is limited. Cycle durations in clinical research ranged from twelve to twenty-four weeks; no robust data exist on optimal cycling practices beyond this.

Oral administration has been explored given AOD-9604's GRAS designation in the United States, which opened regulatory pathways for inclusion in food and cosmetic products. Oral bioavailability is substantially lower than subcutaneous delivery due to first-pass hepatic metabolism and gastrointestinal peptide degradation. Research and anecdotal use protocols typically employ one to two milligrams per day orally to partially compensate, though direct pharmacokinetic comparisons with SC dosing are limited in the published literature.

Subcutaneous injection should use an insulin syringe with a short fine-gauge needle, targeting the subcutaneous fat layer of the abdomen. Site rotation across the injection region is standard practice.

---

Safety Profile

AOD-9604 has demonstrated a notably clean safety profile across available human data. Phase I studies confirmed tolerability at doses up to one milligram per day subcutaneously, with no serious adverse events reported attributable to the compound. Injection-site reactions (minor erythema and transient local discomfort) were the most frequently reported adverse events and resolved without intervention.

Crucially, no GH-axis perturbation has been documented. IGF-1, fasting glucose, fasting insulin, and standard growth-hormone measurements remained within normal reference ranges across Phase I and Phase II cohorts. This distinguishes AOD-9604 sharply from native hGH, which carries well-established risks of glucose dysregulation, fluid retention, carpal tunnel syndrome, and — at chronic supraphysiological doses — acromegalic sequelae.

No immunogenic responses have been reported in clinical studies. The peptide's relatively small size and its derivation from endogenous human sequence may reduce antigenic burden compared with exogenous large-protein hormones. Long-term safety data beyond twenty-four weeks are not available from controlled studies, and this gap should be acknowledged in any risk assessment.

---

Regulatory and Legal Status

In the United States, AOD-9604 has been granted GRAS (Generally Recognised As Safe) status for use as a food ingredient and in cosmetic formulations. This does not constitute approval as a pharmaceutical drug or a therapeutic agent. It is not FDA-approved for any indication and may not be marketed with disease treatment claims.

In the United Kingdom, AOD-9604 holds no medicinal product licence and has not been through MHRA evaluation as a therapeutic. Its manufacture, supply, or administration for therapeutic purposes falls outside current regulatory authorisation. Possession is not illegal under the Misuse of Drugs Act, but supply for human use as a medicine without appropriate authorisation carries regulatory risk under the Human Medicines Regulations 2012.

In the European Union, the position mirrors the UK: no EMA approval, no marketing authorisation, research use only.

This monograph is provided for educational and research reference purposes. It does not constitute medical advice, and AOD-9604 should not be sourced, compounded, or administered outside of properly authorised research contexts.

---

Reconstitution and Storage

AOD-9604 is typically supplied as a lyophilised (freeze-dried) white powder in sterile multi-dose vials, most commonly at five milligrams per vial. Reconstitution should use bacteriostatic water (sterile water containing zero-point-nine percent benzyl alcohol as a preservative). Add bacteriostatic water slowly down the side of the vial — do not inject directly onto the powder pellet — and swirl gently rather than shaking to avoid denaturing the peptide structure.

A typical reconstitution for a three-hundred-microgram daily dose from a five-milligram vial: add two millilitres of bacteriostatic water to yield a concentration of two-point-five milligrams per millilitre. Each daily dose of three hundred micrograms then corresponds to zero-point-twelve millilitres (twelve units on an insulin syringe).

Lyophilised vials should be stored refrigerated at two to eight degrees Celsius, protected from light. Reconstituted solution should be refrigerated and used within twenty-eight days. Do not freeze reconstituted peptide. Discard any vial showing particulate matter, discolouration, or cloudiness.

---

Frequently Asked Questions

Does AOD-9604 raise IGF-1? No. The compound does not activate the GH receptor and consequently does not stimulate hepatic IGF-1 production. This has been confirmed in human cell-line studies and in clinical trial biochemistry panels [PMID:11146367].

Can AOD-9604 be combined with GHRPs or CJC-1295? In research contexts, AOD-9604 has been explored alongside growth hormone secretagogues. Because AOD-9604 acts downstream of the GH receptor independently, it does not duplicate the mechanism of GHRPs, and theoretical additive lipolytic effects have been discussed. See stack resources below for specific investigated combinations.

Is oral AOD-9604 effective? Oral delivery achieves lower plasma concentrations than SC injection due to GI peptide degradation. The one-to-two milligram oral dose range aims to compensate, but no head-to-head human pharmacokinetic comparison has been published. Oral forms carry GRAS regulatory status in the US for food applications.

How long does a research cycle typically run? Clinical studies ran twelve to twenty-four weeks. No validated data exist on optimal cycle length for research purposes.

Is it detectable in sports drug testing? WADA has not specifically listed AOD-9604 as a prohibited substance as of the date of this monograph, but research participants and athletes subject to anti-doping rules should verify current prohibited-list status independently before use.

---

Related Stacks

Explore AOD-9604 in multi-peptide research combinations:

• Tesamorelin + AOD-9604 Visceral Fat Stack
• MOTS-c + AOD-9604 Fat Loss Stack
• Tirzepatide + Retatrutide + AOD-9604 Metabolic Stack

Source research-grade AOD-9604

AOD-9604 — Growth Hormone C-terminal Lipolytic Fragment is sold for laboratory and in vitro research use only. UK regulatory status: Granted GRAS status in the US (food/cosmetic), not approved as a medicinal product. Unapproved in UK/EU for therapeutic use. Research use only..

Source on PeptideBarn.co.ukFull monograph on PeptideAuthority.co.uk